文献速递临床试验与 GCP基础与转化研究

依特卡肽对血液透析患者心脏肥大的影响:一项随机对照试验(ETECAR-HD)

Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).
PubMed 文献 · Trials · 2019-10-24

ETECAR-HD为为期12个月的单盲随机试验,在合并继发性甲状旁腺功能亢进的维持性血液透析患者中比较依特卡肽与阿法骨化醇对左心室肥大及心肌纤维化的影响。主要终点为心脏磁共振测量的左心室质量指数从基线至12个月的变化,样本量计算需随机62例患者以检出组间至少20 g/m2的差异。研究假设依特卡肽降低FGF23可能逆转左心室肥大,但该因果关系尚未被证实。

要点

  • 纳入标准为每周三次血液透析≥3个月且≤3年、甲状旁腺激素≥300 pg/ml并伴左心室肥大者。
  • 主要终点为心脏磁共振测得的左心室质量指数从基线至12个月的变化(g/m2)。
  • 随机按残余肾功能分层,并定期进行体成分监测以控制容量状态。

核心结论

  • 使用拟钙剂降低FGF23以逆转左心室肥大的因果推断与病理生理机制尚未被证实。
  • 该干预研究有望发现维持性血液透析患者心脏肥大与纤维化的新治疗策略。
  • 可推测成功改善心脏形态也将降低该人群的心脏死亡风险。

研究设计与样本

  • 单盲随机对照试验,为期12个月,比较依特卡肽与阿法骨化醇对维持性血液透析合并继发性甲状旁腺功能亢进患者左心室肥大和心肌纤维化的影响。
  • 两种治疗方案均滴定至同等抑制继发性甲状旁腺功能亢进,同时阿法骨化醇使FGF23升高、依特卡肽使FGF23降低。
  • 纳入每周三次血液透析≥3个月且≤3年、甲状旁腺激素≥300 pg/ml并伴左心室肥大的患者。
  • 样本量计算显示需随机62例患者,以在12个月时检出两组间左心室质量指数至少20 g/m2的差异。
  • 随机化按残余肾功能分层,并定期进行体成分监测以控制患者容量状态。

关键数值与推荐

  • 主要终点为心脏磁共振测量的左心室质量指数(g/m2)从基线至12个月的变化。
  • 次要终点包括超声心动图测量的心脏参数、骨代谢生物标志物(FGF23、维生素D、甲状旁腺激素、钙、磷、s-Klotho)。
  • 次要终点还包括心脏标志物(脑钠肽前体、透析前后肌钙蛋白T)及肾素-血管紧张素-醛固酮级联代谢物(血管紧张素I、血管紧张素II、Ang-(1-7)、Ang-(1-5)、Ang-(1-9)和醛固酮)。
  • 研究药物由透析护士在每次血液透析结束后经静脉给药,从而避免依从性问题。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 使用拟钙剂降低FGF23以逆转左心室肥大的因果推断与病理生理机制尚未被证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibroblast growth factor 23 (FGF23) is associated with left ventricular hypertrophy (LVH) in patients with chronic kidney disease, and calcimimetic therapy reduces plasma concentrations of FGF23. It remains unknown whether treatment with the calcimimetic etelcalcetide (ETL) reduces LVH in patients on hemodialysis. METHODS/DESIGN: This single-blinded randomized trial of 12 months duration will test the effects of ETL compared with alfacalcidol on LVH and cardiac fibrosis in maintenance hemodialysis patients with secondary hyperparathyroidism. Both treatment regimens will be titrated to equally suppress secondary hyperparathyroidism while alfacalcidol treatment causes an increase and ETL a decrease in FGF23, respectively. Patients treated thrice weekly with hemodialysis for ≥ 3 months and ≤ 3 years with parathyroid hormone levels ≥ 300 pg/ml and LVH will be enrolled in the study. The primary study endpoint is change from baseline to 12 months in left ventricular mass index (LVMI; g/m2) measured by cardiac magnetic resonance imaging. Sample size calculations showed that 62 randomized patients will be necessary to detect a difference in LVMI of at least 20 g/m2 between the two groups at 12 months. Due to the strong association of volume overload and LVH, randomization will be stratified by residual kidney function, and regular body composition monitoring will be performed to control the volume status of patients. Study medication will be administered intravenously by the dialysis nurses after every hemodialysis session, thus omitting adherence issues. Secondary study endpoints are cardiac parameters measured by echocardiography, biomarker concentrations of bone metabolism (FGF23, vitamin D, parathyroid hormone, calcium, phosphate, s-Klotho), cardiac markers (pro-brain natriuretic peptide, pre- and postdialysis troponin T) and metabolites of the renin-angiotensin-aldosterone cascade (angiotensin I (Ang I), Ang II, Ang-(1-7), Ang-(1-5), Ang-(1-9), and aldosterone). DISCUSSION: The causal inference and pathophysiology of LVH regression by FGF23 reduction using calcimimetic treatment has not yet been shown. This intervention study has the potential to discover a new strategy for the treatment of cardiac hypertrophy and fibrosis in patients on maintenance hemodialysis. It might be speculated that successful treatment of cardiac morphology will also reduce the risk of cardiac death in this population. TRIAL REGISTRATION: European Clinical Trials Database, EudraCT number 2017-000222-35; ClinicalTrials.gov, NCT03182699 . Registered on.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dörr K, Kammer M, Reindl-Schwaighofer R, et al. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD). Trials. 2019. PMID: 31651370. doi:10.1186/s13063-019-3707-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。